Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for InVivo Therapeutics Holdings Corp. (NVIV : NSDQ)
 
 • Company Description   
InVivo Therapeutics Holdings Corp. operates as a medical device company focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company intends to offer three products, including a biocompatible polymer scaffolding device to treat acute wound SCI; a biocompatible hydrogel for local controlled release of methylprednisolone to treat acute SCI; and a biocompatible polymer scaffolding device seeded with autologous hNSCs to treat acute and chronic SCI. InVivo Therapeutics Holdings Corp. is based in Cambridge, Massachusetts.

Number of Employees: 6

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.24 Daily Weekly Monthly
20 Day Moving Average: 18,992 shares
Shares Outstanding: 3.11 (millions)
Market Capitalization: $3.85 (millions)
Beta: 0.83
52 Week High: $13.77
52 Week Low: $0.81
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -6.77% -10.30%
12 Week 8.77% 0.97%
Year To Date -47.23% -52.00%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
ONE KENDALL SQUARE SUITE B14402
-
CAMBRIDGE,MA 02139
USA
ph: 617-863-5500
fax: -
info@invivotherapeutics.com http://www.invivotherapeutics.com
 
 • General Corporate Information   
Officers
Richard Toselli - Chief Executive Officer;President
C. Ann Merrifield - Chair of the Board
Richard Christopher - Chief Financial Officer
Heather Hamel - Chief Legal Officer and General Counsel
Daniel R. Marshak - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 46186M605
SIC: 3841
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/22
Next Expected EPS Date: 06/06/23
Share - Related Items
Shares Outstanding: 3.11
Most Recent Split Date: 4.00 (0.04:1)
Beta: 0.83
Market Capitalization: $3.85 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 06/06/23  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.26
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -13.14%
vs. Previous Quarter: -0.51%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/23 - -78.01
12/31/22 - -77.46
09/30/22 - -78.11
ROA
03/31/23 - -63.64
12/31/22 - -62.83
09/30/22 - -63.33
Current Ratio
03/31/23 - 8.85
12/31/22 - 7.13
09/30/22 - 4.62
Quick Ratio
03/31/23 - 8.85
12/31/22 - 7.13
09/30/22 - 4.62
Operating Margin
03/31/23 - -
12/31/22 - -
09/30/22 - -
Net Margin
03/31/23 - -
12/31/22 - -
09/30/22 - -
Pre-Tax Margin
03/31/23 - -
12/31/22 - -
09/30/22 - -
Book Value
03/31/23 - 4.34
12/31/22 - 6.48
09/30/22 - 7.26
Inventory Turnover
03/31/23 - -
12/31/22 - -
09/30/22 - -
Debt-to-Equity
03/31/23 - 0.00
12/31/22 - 0.00
09/30/22 - 0.00
Debt-to-Capital
03/31/23 - 0.00
12/31/22 - 0.00
09/30/22 - 0.00
 

Powered by Zacks Investment Research ©